Institutional members access full text with Ovid®

Share this article on:

Preoperative Chemoradiation for Borderline Resectable Pancreatic Cancer: The New Standard?

Katz, Matthew HG, MD; Kim, Michael P., MD; Tzeng, Ching-Wei, MD; Lee, Jeffrey E., MD

doi: 10.1097/SLA.0000000000002783
Features

The Pancreatic Surgery Service, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.

Reprints: Matthew HG Katz, MD, FACS, Chief, Pancreatic Surgery Service, Associate Professor, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, FCT 17.6058, Unit #1484, Houston, TX 77030-4009. E-mail: mhgkatz@mdanderson.org.

Editorial to accompany publication of: “Oncologic benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial” by Choi and colleagues.

The authors declare no conflicts of interest.

Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.